Press Release Archive

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced data from ORAL Sync (A3921046) and Study A3921109, two clinical trials of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor, being studied in rheumatoid arthritis (RA). Top-line results of ORAL Sync, a pivotal Phase 3 trial, were announced earlier this year. A separate trial, Study A3921109, evaluated the safety and efficacy of atorvastatin versus

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.1,2 “We are delighted that

(BUSINESS WIRE)--Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95%CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population. PFS

(BUSINESS WIRE)--Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,1 crizotinib,2 and bosutinib,3 as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,4,5 at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. The Company will also share analyses from early stage compounds focused on the science behind tumor

(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the Alzheimer’s Association™, the world's leading voluntary health organization in Alzheimer's care, support and research, as a new beneficiary of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. Through this campaign, mountaineer and Alzheimer’s disease advocate

(BUSINESS WIRE)--Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. “Pulmonary arterial

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) First-Quarter 2011 2010 Change

(BUSINESS WIRE)--It’s not what celebrities know about getting fit for summer, it’s who they know. And when Hollywood stars want to get in the best shape of their lives, they call Harley Pasternak, creator of the 5 Factor Diet. This spring, the makers of Centrum® multivitamins are teaming up with Pasternak to bring star-worthy tips to Americans. One lucky person will win a trip to Los Angeles and a training session with Harley, a renowned

(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Standard (A3921064) and ORAL Step (A3921032) Phase 3 studies of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor. ORAL Standard is a completed twelve-month study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive